Information  X 
Enter a valid email address

Company Name matching 'Sequana Medical NV'

Date
Time Source
Company
Announcement
21 Jan 2022 5:00 pm GNW   Sequana Medical NV SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
17 Dec 2021 6:00 am GNW   Sequana Medical NV Sequana Medical to attend 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright BIOCONNECT Virtual Conference
07 Dec 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces positive interim results of SAHARA DESERT, the alfapump DSR® study in heart failure patients with persistent congestion
06 Dec 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces the completion of patient enrolment in POSEIDON, the North American pivotal alfapump® study
09 Nov 2021 6:00 am GNW   Sequana Medical NV Sequana Medical to present at Jefferies London Healthcare Conference
03 Nov 2021 6:00 am GNW   Sequana Medical NV Sequana Medical receives MDSAP certification and expands its Quality Management System towards North America
04 Oct 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)
28 Sep 2021 6:00 am GNW   Sequana Medical NV Sequana Medical to present at 8th Annual HealthTech Investment Forum
02 Sep 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces H1 2021 results and provides business update
31 Aug 2021 6:00 am GNW   Sequana Medical NV Sequana Medical appoints Jackie Fielding, former Medtronic VP, to its Board of Directors
26 Aug 2021 6:00 am GNW   Sequana Medical NV Sequana Medical Notice of 2021 Half Year Results and Business Update
27 Jul 2021 5:00 pm GNW   Sequana Medical NV SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
06 Jul 2021 6:00 am GNW   Sequana Medical NV Sequana Medical’s results from RED DESERT alfapump DSR® study presented as one of the Highlights at Heart Failure 2021 Online Congress
01 Jul 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump® study (POSEIDON)
17 Jun 2021 6:00 am GNW   Sequana Medical NV Sequana Medical to Host a Key Opinion Leader Webinar on “The Impact of Liver Ascites on Patients and Healthcare Systems and the potential of alfapump® therapy in NASH-related ascites”
09 Jun 2021 6:00 am GNW   Sequana Medical NV Results from Sequana Medical’s RED DESERT alfapump DSR® study selected for presentation at the Heart Failure 2021 Online Congress
01 Jun 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces first patient enrolled in SAHARA DESERT
27 May 2021 5:00 pm GNW   Sequana Medical NV Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders
11 May 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces strong top-line results from RED DESERT alfapump DSR® study and expansion of DSR® development programme
03 May 2021 6:00 am GNW   Sequana Medical NV Sequana Medical Announces New Share Capital Amount and New Number of Shares
27 Apr 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 27 May 2021
25 Mar 2021 5:00 pm GNW   Sequana Medical NV SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
17 Mar 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces 2020 Full Year Results and 2021 Outlook
10 Mar 2021 6:00 am GNW   Sequana Medical NV Sequana Medical Notice of 2020 Full Year Results and Business Update
23 Feb 2021 5:00 pm GNW   Sequana Medical NV Transparency Notifications from Shareholders
16 Feb 2021 6:00 am GNW   Sequana Medical NV SEQUANA MEDICAL'S NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
15 Feb 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces February-March 2021 Investor Conference Schedule
09 Feb 2021 8:15 pm GNW   Sequana Medical NV SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 22.5 MILLION IN AN EQUITY PLACEMENT
  1:30 pm GNW   Sequana Medical NV SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT
04 Feb 2021 6:00 am GNW   Sequana Medical NV Sequana Medical announces granting of key alfapump DSR® patents in U.S. and Europe
17 Dec 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces January 2021 Investor Conference Schedule
07 Dec 2020 6:00 am GNW   Sequana Medical NV Sequana Medical to host KOL event on “The challenge of diuretic resistance in the management of heart failure patients and the potential for alfapump® DSR therapy”
19 Nov 2020 7:00 am GNW   Sequana Medical NV Sequana Medical announces positive interim data from North American pivotal alfapump® study (POSEIDON)
12 Nov 2020 6:00 am GNW   Sequana Medical NV Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference
22 Oct 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces strong interim results from RED DESERT alfapump® DSR study and provides business update
15 Oct 2020 6:00 am GNW   Sequana Medical NV Sequana Medical appoints two additional experts as Heart Failure Scientific Advisors
09 Sep 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces September 2020 Investor Conference Schedule
03 Sep 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces H1 2020 results and provides business update
27 Aug 2020 6:00 am GNW   Sequana Medical NV Sequana Medical Notice of 2020 Half Year Results and Business Update
28 Jul 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces €7.3 million debt financing and provides clinical update
25 Jun 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces listing of 644,287 existing shares on Euronext Brussels following January 2020 Equity Placement
17 Jun 2020 6:00 am GNW   Sequana Medical NV Sequana Medical to present at digital Investor Events
16 Jun 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces that the results of the alfapump® MOSAIC study have been published in Liver Transplantation
28 May 2020 5:00 pm GNW   Sequana Medical NV Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders
04 May 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces the appointment of Dr Oliver Gödje as Chief Medical Officer
28 Apr 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 28 May 2020
19 Mar 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces 2019 Full Year Results and 2020 Outlook
12 Mar 2020 6:00 am GNW   Sequana Medical NV Sequana Medical Notice of 2019 Full Year Results and 2020 Outlook
21 Feb 2020 6:00 am GNW   Sequana Medical NV Transparency Notifications from Shareholders
03 Feb 2020 4:45 pm GNW   Sequana Medical NV Transparency Notifications from Shareholders
29 Jan 2020 6:00 am GNW   Sequana Medical NV Sequana Medical Announces New Share Capital Amount and New Number of Shares
22 Jan 2020 8:31 pm GNW   Sequana Medical NV Sequana Medical Successfully Raises Eur 19.0 Million in an Equity Placement
  2:48 pm GNW   Sequana Medical NV SEQUANA MEDICAL LAUNCHES EQUITY PLACEMENT
10 Jan 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces first-in-human data of Direct Sodium Removal (DSR) therapy published in Circulation
07 Jan 2020 6:00 am GNW   Sequana Medical NV Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients
25 Sep 2019 6:05 am GNW   Sequana Medical NV Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update
  6:00 am GNW   Sequana Medical NV Sequana Medical announces first patient enrolled in North American alfapump® pivotal study (POSEIDON)
19 Sep 2019 6:00 am GNW   Sequana Medical NV Sequana Medical appoints leading experts as Heart Failure Scientific Advisors
14 Aug 2019 6:00 am GNW   Sequana Medical NV Sequana Medical announces date change for Half Year 2019 Business Update and Financial Results
04 Jun 2019 6:00 am GNW   Sequana Medical NV Sequana Medical announces unconditional IDE approval from U.S. FDA to start alfapump® pivotal study (POSEIDON)


Company Announcements Archive »


a d v e r t i s e m e n t